SEARCH

SEARCH BY CITATION

References

  • 1
    National Osteoporosis Foundation. Clinician's guide to prevention and treatment osteoporosis [Internet]. Washington (DC): National Osteoporosis Foundation; 2013 [cited 2013 Aug 05]. Available at: http://www.nof.org/files/nof/public/content/resource/913/files/580.pdf.
  • 2
    Body JJ. How to manage postmenopausal osteoporosis? Acta Clin Belg. 2011; 66:4437.
  • 3
    U.S. Food and Drug Administration (FDA). Drug Safety Newsletter. 2009;Volume 2, Number 2 [Internet]. Silver Spring (MD): U.S. Food and Drug Administration; 2009 [cited 2013 Aug 05]. Available at: http://www.fda.gov/downloads/Drugs/DrugSafety/DrugSafetyNewsletter/UCM168579.pdf.
  • 4
    U.S. Food and Drug Administration (FDA). FDA Drug Safety Communication: New contraindication and updated warning on kidney impairment for Reclast (zoledronic acid) [Internet]. Silver Spring (MD): U.S. Food and Drug Administration; 2011 [cited 2013 Aug 05]. Available at: http://www.fda.gov/Drugs/DrugSafety/ucm270199.htm.
  • 5
    Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron. 1976; 16:3141.
  • 6
    Reclast [prescribing information]. Stein, Switzerland: Novartis Pharma Stein AG; 2011.
  • 7
    Actonel [prescribing information]. Manati, Puerto Rico:Warner Chilcott Puerto Rico LLC; 2011.
  • 8
    Bonviva [summary of product characteristics]. Welwyn Garden City, UK: Roche Products Ltd; 2011.
  • 9
    Fosamax [summary of product characteristics]. Hoddesdon, Hertfordshire, UK: Merck, Sharp and Dohme Limited; 2011.
  • 10
    Klawansky S, Komaroff E, Cavanaugh PF Jr, et al. Relationship between age, renal function and bone mineral density in the US population. Osteoporos Int. 2003; 14:5706.
  • 11
    Widler L, Jaeggi KA, Glatt M, et al. Highly potent geminal bisphosphonates. From pamidronate disodium (Aredia) to zoledronic acid (Zometa). J Med Chem. 2002; 45:372138.
  • 12
    Russell RG. Bisphosphonates: the first 40 years. Bone. 2011; 49:219.
  • 13
    Russell RG, Watts NB, Ebetino FH, Rogers MJ. Mechanisms of action of bisphosphonates: similarities and differences and their potential influence on clinical efficacy. Osteoporos Int. 2008; 19:73359.
  • 14
    Luhe A, Kunkele KP, Haiker M, et al. Preclinical evidence for nitrogen-containing bisphosphonate inhibition of farnesyl diphosphate (FPP) synthase in the kidney: implications for renal safety. Toxicol In Vitro. 2008; 22:899909.
  • 15
    Troehler U, Bonjour JP, Fleisch H. Renal secretion of diphosphonates in rats. Kidney Int. 1975; 8:613.
  • 16
    Choudhury D, Ahmed Z. Drug-associated renal dysfunction and injury. Nat Clin Pract Nephrol. 2006; 2:8091.
  • 17
    Bounameaux HM, Schifferli J, Montani JP, Jung A, Chatelanat F. Renal failure associated with intravenous diphosphonates. Lancet. 1983; 1:471.
  • 18
    Fleisch H. Bisphosphonates: mechanisms of action. Endocr Rev. 1998; 19:80100.
  • 19
    Green JR, Seltenmeyer Y, Jaeggi KA, Widler L. Renal tolerability profile of novel, potent bisphosphonates in two short-term rat models. Pharmacol Toxicol. 1997; 80:22530.
  • 20
    Markowitz GS, Fine PL, Stack JI, et al. Toxic acute tubular necrosis following treatment with zoledronate (Zometa). Kidney Int. 2003; 64:2819.
  • 21
    Bodmer M, Amico P, Mihatsch MJ, et al. Focal segmental glomerulosclerosis associated with long-term treatment with zoledronate in a myeloma patient. Nephrol Dial Transplant. 2007; 22:236670.
  • 22
    Joensuu TK. Renal toxicity following zoledronic acid reversed with ibandronate in a prostate cancer patient with bone metastases. Urol Int. 2008; 80:44850.
  • 23
    Henley D, Kaye J, Walsh J, Cull G. Symptomatic hypocalcaemia and renal impairment associated with bisphosphonate treatment in patients with multiple myeloma. Intern Med J. 2005; 35:7268.
  • 24
    Body JJ, Pfister T, Bauss F. Preclinical perspectives on bisphosphonate renal safety. Oncologist. 2005; 10(Suppl 1):37.
  • 25
    Zometa [summary of product characteristics]. Frimley, Surrey: Novartis Pharmaceuticals UK Ltd.
  • 26
    Kintzel PE. Anticancer drug-induced kidney disorders. Drug Saf. 2001; 24:1938.
  • 27
    Janus N, Launay-vacher V, Byloos E, et al. Cancer and renal insufficiency results of the BIRMA study. Br J Cancer. 2010; 103:181521.
  • 28
    Dimopoulos MA, Terpos E. Renal insufficiency and failure. Hematology. 2010; 1:4316.
  • 29
    Strewler GJ, Nissenson RA. Hypercalcemia in malignancy. West J Med. 1990; 153:63540.
  • 30
    Rosen LS, Gordon D, Kaminski M, et al. Long-term efficacy and safety of zoledronic acid compared with pamidronate disodium in the treatment of skeletal complications in patients with advanced multiple myeloma or breast carcinoma: a randomized, double-blind, multicenter, comparative trial. Cancer. 2003; 98:173544.
  • 31
    Saad F, Gleason DM, Murray R, et al. Zoledronic Acid Prostate Cancer Study Group. A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma. J Natl Cancer Inst. 2002; 94:145868.
  • 32
    Jamal SA, Bauer DC, Ensrud KE, Cauley JA, Hochberg M, Ishani A, Cummings SR. Alendronate treatment in women with normal to severely impaired renal function: an analysis of the fracture intervention trial. J Bone Miner Res. 2007; 22:5038.
  • 33
    Miller PD, Roux C, Boonen S, Barton IP, Dunlap LE, Burgio DE. Safety and efficacy of risedronate in patients with age-related reduced renal function as estimated by the Cockcroft and Gault method: a pooled analysis of nine clinical trials. J Bone Miner Res. 2005; 20:210515.
  • 34
    Chesnut CH III, Skag A, Christiansen C, et al. Effects of oral ibandronate administered daily or intermittently on fracture risk in postmenopausal osteoporosis. J Bone Miner Res. 2004; 19:12419.
  • 35
    Miller PD, McClung MR, Macovei L, et al. Monthly oral ibandronate therapy in postmenopausal osteoporosis 1-year results from the MOBILE study. J Bone Miner Res. 2005; 20:131522.
  • 36
    Eisman JA, Civitelli R, Adami S, et al. Efficacy and tolerability of intravenous ibandronate injections in postmenopausal osteoporosis: 2-year results from the DIVA study. J Rheumatol. 2008; 35:48897.
  • 37
    Black DM, Delmas PD, Eastell R, et al. Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis. N Engl J Med. 2007; 356:180922.
  • 38
    Lyles KW, Colon-Emeric CS, Magaziner JS, et al. Zoledronic acid and clinical fractures and mortality after hip fracture. N Engl J Med. 2007; 357:1799809.
  • 39
    Reid DM, Devogelaer JP, Saag K, et al. Zoledronic acid and risedronate in the prevention and treatment of glucocorticoid-induced osteoporosis (HORIZON): a multicentre, double-blind, double-dummy, randomised controlled trial. Lancet. 2009; 373:125363.
  • 40
    Miller PD, Ragi-Eis S, Mautalan C, Ramimeriz F, Jonkamski I. Effects of intravenous ibandronate injection on renal function in women with postmenopausal osteoporosis at high risk for renal disease—the DIVINE study. Bone. 2011; 49:131722.
  • 41
    Black DM, Cummings SR, Karpf DB, et al. Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Fracture Intervention Trial Research Group. Lancet. 1996; 348:153541.
  • 42
    Black DM, Thompson DE, Bauer DC. et al; Fracture Intervention Trial. Fracture risk reduction with alendronate in women with osteoporosis: the Fracture Intervention Trial. FIT Research Group. J Clin Endocrinol Metab. 2000; 85:411824.
  • 43
    Cummings SR, Black DM, Thompson DE, et al. Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures: results from the Fracture Intervention Trial. JAMA. 1998; 280:207782.
  • 44
    Black DM, Schwartz AV, Ensrud KE. et al, FLEX Research Group. Effects of continuing or stopping alendronate after 5 years of treatment: the Fracture Intervention Trial Long-term Extension (FLEX): a randomized trial. JAMA. 2006; 296:292738.
  • 45
    Yanik B, Bavbek N, Yanik T, et al. The effect of alendronate, risedronate, and raloxifene on renal functions, based on the Cockcroft and Gault method, in postmenopausal women. Ren Fail. 2007; 29:4716.
  • 46
    Delmas PD, Adami S, Strugala C, et al. Intravenous ibandronate injections in postmenopausal women with osteoporosis: one-year results from the dosing intravenous administration study. Arthritis Rheum. 2006; 54:183846.
  • 47
    Boonen S, Sellmeyer DE, Lippuner K, et al. Renal safety of annual zoledronic acid infusions in osteoporotic postmenopausal women. Kidney Int. 2008; 74:6418.
  • 48
    Miller PD, Black DM, Hruska J, Boonen S. Renal effects of treatment with zoledronic acid: results from the HORIZON-PFT extension study. Osteoporos Int. 2012; 23:S1978.
  • 49
    Regnister J, Minne HW, Sorensen OH, et al. Randomized trial of the effects of risedronate on vertebral fractures in women with established postmenopausal osteoporosis. Vertebral Efficacy with Risedronate Therapy (VERT) Study Group. Osteoporos Int. 2000; 11:8391.
  • 50
    Reginster JY, Adami S, Lakatos P, et al. Efficacy and tolerability of once-monthly oral ibandronate in postmenopausal osteoporosis: 2 year results from the MOBILE study. Ann Rheum Dis. 2006; 65:65461.
  • 51
    Black DM, Reid IR, Boonen S, et al. The effect of 3 versus 6 years of zoledronic acid treatment of osteoporosis: a randomized extension to the HORIZON-Pivotal Fracture Trial (PFT). J Bone Miner Res. 2011; 27:24354.
  • 52
    Boonen S, Reginster J-Y, Kaufman J-M, et al. Fracture risk and zoledronic acid therapy in men with osteoporosis. N Engl J Med. 2012; 367:171423.
  • 53
    European Medicines Agency. Aclasta: Procedural steps taken and scientific information after authorisation. London (UK): European Medicines Agency; 2012 [cited 2013 Aug 05]. Available at: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Procedural_steps_taken_and_scientific_information_after_authorisation/human/000595/WC500020935.pdf.
  • 54
    Glassock RJ, Winearls C. Ageing and the glomerular filtration rate: truths and consequences. Trans Am Clin Climatol Assoc. 2009; 120:41928.
  • 55
    Abdelhafiz AH, Brown SH, Bello A, El Nahas M. Chronic kidney disease in older people: physiology, pathology or both? Nephron Clin Pract. 2010; 116:c1924.
  • 56
    Tonelli M, Muntner P, Lloyd A, et al.; Alberta Kidney Disease Network. Using proteinuria and estimated glomerular filtration rate to classify risk in patients with chronic kidney disease: a cohort study. Ann Intern Med. 2011; 154:1221.
  • 57
    National Kidney Foundation. KDOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Am J Kidney Dis. 2002; 39:S1266.
  • 58
    Ensrud KE, Lui LY, Taylor BC, et al. Renal function and risk of hip and vertebral fractures in older women. Arch Intern Med. 2007; 167:1339.
  • 59
    Fried LF, Biggs ML, Shlipak MG, et al. Association of kidney function with incident hip fracture in older adults. J Am Soc Nephrol. 2007; 18:2826.
  • 60
    Jamal S, West S, Miller PF. Fracture risk assessment in patients with chronic kidney disease. Osteoporos Int. 2012; 23:11918.
  • 61
    Hruska KA, Saab G, Chaudhary LR, Quinn CO, Lund RJ, Surendran K. Kidney-bone, bone-kidney, and cell-cell communications in renal osteodystrophy. Semin Nephrol. 2004; 24:2538.
  • 62
    Miller PD. The kidney and bisphosphonates. Bone. 2011; 49:7781.
  • 63
    Nickolas TL, Cremers S, Zhang A, et al. Determinates of prevalent fractures in chronic kidney disease. J Am Soc Nephro. 2011; 22:15607.
  • 64
    Nickolas TL. BMD and fracture risk in CKD: where should we go from here? Clin J Am Soc Nephrol. 2012; 7:105860.
  • 65
    Isakova T, Wahl P, Vargas GS, et al. Fibroblast growth factor 23 is elevated before parathyroid hormone and phosphate in chronic kidney disease. Kidney Int. 2011; 79:13708.
  • 66
    Isakova T, Xie H, Yang W. et al Chronic Renal Insufficiency Cohort (CRIC) Study Group. Fibroblast growth factor 23 and risks of mortality and end-stage renal disease in patients with chronic kidney disease. JAMA. 2011; 305:24329.
  • 67
    Jüppner H, Wolf M, Salusky IB. FGF-23: more than a regulator of renal phosphate handling? J Bone Miner Res. 2010; 25:20917.
  • 68
    Sambrook PN, Camerson ID, Chen JS, et al. Oral bisphosphonates are associated with reduced mortality in frail older people: a prospective five year study. Osteoporos Int. 2011; 22:25516.
  • 69
    Cannata-Andía JB, Rodriguez García M, Gómez Alonso C. Osteoporosis and adynamic bone in chronic kidney disease. J Nephrol. 2013; 26:7380.
  • 70
    Miller PD. Osteoporosis in patients with chronic kidney disease: diagnosis, evaluation, and management. In: Basow DS, editor. UpToDate. Waltham, MA: UpToDate; [cited 2013 Aug 05]. Available at: http://www.uptodate.com/contents/osteoporosis-in-patients-with-chronic-kidney-disease-diagnosis-evaluation-and-management?detectedLanguage=en&source=search_result&search=Miller+osteoporosis&selectedTitle=1∼150&provider=noProvider. 2013.
  • 71
    Coen G. Adynamic bone disease: an update and overview. J Nephrol. 2005; 18:11722.
  • 72
    Hruska KA, Saab G, Mathew S, Lund R. Renal osteodystrophy, phosphate homeostasis, and vascular calcification. Semin Dial. 2007; 20:30915.
  • 73
    Thompson B, Towler DA. Arterial calcification and bone physiology: role of the bone-vascular axis. Nat Rev Endocrinol. 2012; 8:52943.
  • 74
    London GM, Marty C, Marchais SJ, Guerin AP, Metivier F, de Vernejoul MC. Arterial calcifications and bone histomorphometry in end-stage renal disease. J Am Soc Nephrol. 2004; 15:194351.
  • 75
    Frazão JM, Martins P. Adynamic bone disease: clinical and therapeutic implications. Curr Opin Nephrol Hypertens. 2009; 18:3037.
  • 76
    Jamal SA, West SL, Miller PD. Bone and kidney disease: diagnostic and therapeutic implications. Curr Rheumatol Rep. 2012; 14:21723.
  • 77
    Garrett G, Sardiwal S, Lamb EJ, Goldsmith DJ. PTH: a particularly tricky hormone: why measure it at all in kidney patients? Clin J Am Soc Nephrol. 2013; 8:299312.
  • 78
    Duru OK, Vargas RB, Kermah D, Nissenson AR, Norris KC. High prevalence of stage 3 chronic kidney disease in older adults despite normal serum creatinine. J Gen Intern Med. 2009; 24:8692.
  • 79
    Levey AS, Bosch J, Coggins C, et al. Effects of diet and antihypertensive therapy on creatinine clearance and serum creatinine concentration in the Modification of Diet in Renal Disease Study. J Am Soc Nephrol. 1996; 7:5566.
  • 80
    Levey AS, Bosch J, Lewis JB, Greene T, Rogers N, Roth D. A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group. Ann Intern Med. 1999; 130:46170.
  • 81
    National Kidney Disease Education Program. Laboratory evaluation: GFR. Bethesda (MD): National Kidney Disease Education Program (NKDEP), National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), National Institutes of Health (NIH), U.S. Department of Health & Human Services (HHS); 2011 [cited 2013 Aug 05] Available at: http://www.nkdep.nih.gov/labprofessionals/estimate_report_gfr.htm.
  • 82
    Kingdon EJ, Knight CJ, Dunstan K, et al. Calculated glomerular filtration rate is a useful screening tool to identify scleroderma patients with renal impairment. Rheumatology. 2002; 42:2633.
  • 83
    Stevens LA, Coresh J, Greene T, Levey AS. Assessing kidney function--measured and estimated glomerular filtration rate. N Engl J Med. 2006; 354:247383.
  • 84
    Levey AS, Stevens LA, Schmid CH, et al.; CKD-EPI (Chronic Kidney Disease Epidemiology Collaboration). A new equation to estimate glomerular filtration rate. Ann Intern Med. 2009; 150:60412.
  • 85
    Stevens LA, Li S, Kurella Tamura M, Chen SC, Vassalotti JA, Norris KC, Whaley-Connell AT, Bakris GL, McCullough PA. Comparison of the CKD Epidemiology Collaboration (CKD-EPI) and Modification of Diet in Renal Disease (MDRD) study equations: risk factors for and complications of CKD and mortality in the Kidney Early Evaluation Program (KEEP). Am J Kidney Dis. 2011; 57(3 Suppl 2):S916.
  • 86
    Shafi T, Matsushita K, Selvin E, et al. Comparing the association of GFR estimated by the CKD-EPI and MDRD study equations and mortality: the third national health and nutrition examination survey (NHANES III) examination survey (NHANES III). BMC Nephrol. 2012; 13:42.
  • 87
    Miller PD. Fragility fractures in chronic kidney disease: an opinion-based approach. Cleve Clin J Med. 2009; 76:71523.
  • 88
    Shih AW, Weir MA, Clemens KK, et al. Oral bisphosphonate use in the elderly is not associated with acute kidney injury. Kidney Int. 2012; 82:9038.
  • 89
    Tangri N, Stevens LA, Griffith J, Tighiouart H, Djurdjev O, Naimark D, Levin A, Levey AS. A predictive model for progression of chronic kidney disease to kidney failure. JAMA. 2011; 305:15539.
  • 90
    Kidney Disease: Improving Global Outcomes (KDIGO) CKD–MBD Work Group. KDIGO clinical practice guideline for the diagnosis, evaluation, prevention, and treatment of chronic kidney disease–mineral and bone disorder (CKD–MBD). Kidney Int. 2009; 76(Suppl 113):S1130.
  • 91
    Perazella MA, Markowitz GS. Bisphosphonate nephrotoxicity. Kidney Int. 2008; 74:138593.
  • 92
    Khosla S, Bilezikian JP, Dempster DW, et al. Benefits and risks of bisphosphonate therapy for osteoporosis. J Clin Endocrinol Metab. 2012; 97:227282.
  • 93
    McClung M, Harris ST, Miller PD, et al. Bisphosphonate therapy for osteoporosis: benefits, risks, and drug holiday. Am J Med. 2013; 126:1320.